Please login to the form below

Not currently logged in
Email:
Password:

Immunocore

This page shows the latest Immunocore news and features for those working in and with pharma, biotech and healthcare.

UK biotech beats fundraising records in 2015, says BIA

UK biotech beats fundraising records in 2015, says BIA

BIA chief executive Steve Bates pointed to examples such as Immunocore's record-breaking £205m round as evidence of a growing maturity in the UK sector as it strives to become

Latest news

More from news
Approximately 6 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Pharma deals in July 2015 Pharma deals in July 2015

    This month, Immunocore which develops T-cell receptor based drugs and has a lead product in Phase IIa, raised $320m (£205m) via a private financing round from a syndicate of investors, ... It is hoped that Immunocore and Mereo are signs that at long

  • Pharma deals in March 2015 Pharma deals in March 2015

    Sir John Bell, Regius Professor of Medicine at Oxford University and a non-executive director of Immunocore has criticised the City of London for failing to provide financial support to life

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    30. Immunocore/ Eli Lilly. Co-discovery /co-development, options (cost/profit share). ImmTAC (Immune mobilising mTCR Against Cancer) technology (discovery).

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    Other deals include an alliance with the UK biotech Immunocore via AZ's MedImmune subsidiary and an expansion of an existing personalised drug partnership with Horizon Discovery. “

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    337.5. Immunocore/AZ Medimmune. Collaboration and licence. Immune mobilising monoclonal T-Cell receptor against cancer (ImmTAC) therapies.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Immunocore appoints chief financial officer Immunocore appoints chief financial officer

    Oxford, UK-based Immunocore has appointed Paul Fry as its chief financial officer. ... As Immunocore continues to grow we are continually looking for outstanding individuals such as Paul to complement our team.

  • Immunocore names CEO Immunocore names CEO

    The UK-based biotech Immunocore has appointed industry veteran Dr Eliot Forster as CEO. ... His significant drug development experience will be invaluable to Immunocore as we continue to deliver within our partnerships and advance our proprietary ImmTAC

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics